Legal status by country
Is BNP and nesiritide legal?
Written by Aaron CuhaReviewed Sep 2026
How BNP and nesiritide is classified in the United States, United Kingdom, Australia and Canada, side by side. Each country has its own page with a direct answer, the regulator's approval status and what the classification means in practice.
All four countries, side by side
| Attribute | United States · FDA | United Kingdom · MHRA | Australia · TGA | Canada · Health Canada |
|---|---|---|---|---|
| Status | Not approved | Not approved | Not approved | Not approved |
| Classification | Approved, product discontinued | Not licensed | Not registered | Not approved |
| Note | NDA 020920 (NATRECOR, Scios LLC) is listed Discontinued in Drugs@FDA as of 11 September 2026, and the record carries the Federal Register determination that the product was not discontinued or withdrawn for safety or effectiveness reasons. No current label was returned by the openFDA label database. | None recorded | None recorded | None recorded |
US FDA status: NATRECOR (nesiritide), NDA 020920, Scios LLC, originally approved in 2001 for acutely decompensated heart failure. On the Drugs@FDA query of 11 September 2026 the product is listed Discontinued, with the Federal Register determination that it was not discontinued or withdrawn for safety or effectiveness reasons. BNP and NT-proBNP remain in routine use as diagnostic blood tests, which is a laboratory use, not a drug approval.. Reviewed Sep 2026.
Related compounds
General information current as of Sep 2026, not legal advice. Classifications change; confirm with the regulator or a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships.